• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化患者中 King 简短间质性肺病问卷(K-BILD)与用力肺活量的最小有意义差异。

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

机构信息

King's College London, Division of Asthma, Allergy and Lung Biology, Denmark Hill, London SE5 9RS, UK.

出版信息

Respir Med. 2013 Sep;107(9):1438-43. doi: 10.1016/j.rmed.2013.06.009. Epub 2013 Jul 16.

DOI:10.1016/j.rmed.2013.06.009
PMID:23867809
Abstract

Health status and forced vital capacity (FVC) are widely used outcome measures of interstitial lung disease (ILD) but there is a paucity of studies reporting the minimal clinically meaningful change in these parameters. A study was undertaken to assess the minimal important difference (MID) of an ILD specific health status questionnaire, the King's Brief ILD questionnaire (K-BILD) and that of FVC in a range of ILDs. 57 patients with ILD (17 idiopathic pulmonary fibrosis; IPF) completed the K-BILD (score range 0-100) at 2 separate clinic visits. Patients underwent spirometry at both visits. The MID was determined by a range of distribution methods (Standard error of mean: SEM and 0.3× Effect size: ES) and anchor based methods (objective: FVC and subjective: global rating of change questionnaires, GRCQ). The MID was derived by calculating an average of all methods. Health status was reduced at baseline in all patients, mean (SD) K-BILD total score 62(23). The average MID for K-BILD total score incorporating all methods was an 8 unit change (range 6-10). The average MID for FVC was a 6% change of baseline (range 4-7%). The K-BILD is a responsive patient reported outcome measure for patients with ILD. It can potentially be used to assess patients in the clinic and evaluate the response to therapy. The MID of the K-BILD total score is 8 units. The MID for FVC for a range of ILDs was 6%, similar to that reported recently for patients with IPF. Our findings will facilitate the clinical interpretation of health status and FVC data in ILD.

摘要

健康状况和用力肺活量(FVC)是广泛用于间质性肺疾病(ILD)的结局测量指标,但有关这些参数的临床意义最小变化的研究较少。本研究旨在评估ILD 特定健康状况问卷,即 King's Brief ILD 问卷(K-BILD)和 FVC 的最小临床意义差异(MID)在一系列 ILD 中的变化。57 名ILD 患者(17 名特发性肺纤维化;IPF)在 2 次单独的就诊时完成了 K-BILD(评分范围 0-100)。患者在两次就诊时都接受了肺量测定。MID 通过一系列分布方法(均数标准误:SEM 和 0.3×效应量:ES)和基于锚的方法(客观:FVC 和主观:全球变化评估问卷,GRCQ)来确定。MID 通过计算所有方法的平均值得出。所有患者的基线健康状况均下降,平均(SD)K-BILD 总分 62(23)。纳入所有方法的 K-BILD 总分平均 MID 为 8 个单位的变化(范围为 6-10)。FVC 的平均 MID 是基线的 6%变化(范围为 4-7%)。K-BILD 是一种对 ILD 患者有反应的患者报告结局测量指标。它可以潜在地用于评估诊所中的患者并评估治疗反应。K-BILD 总分的 MID 为 8 个单位。ILD 患者 FVC 的 MID 为 6%,与最近报道的 IPF 患者相似。我们的发现将有助于ILD 中健康状况和 FVC 数据的临床解释。

相似文献

1
The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.特发性肺纤维化患者中 King 简短间质性肺病问卷(K-BILD)与用力肺活量的最小有意义差异。
Respir Med. 2013 Sep;107(9):1438-43. doi: 10.1016/j.rmed.2013.06.009. Epub 2013 Jul 16.
2
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire.《国王简短间质性肺病(K-BILD)健康状况问卷的制定与验证》。
Thorax. 2012 Sep;67(9):804-10. doi: 10.1136/thoraxjnl-2012-201581. Epub 2012 May 3.
3
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.《King's 简要间质性肺病问卷的心理测量特性及其在进行性纤维化间质性肺病患者中治疗反应有意义的阈值》
Eur Respir J. 2022 Jun 2;59(6). doi: 10.1183/13993003.01790-2021. Print 2022 Jun.
4
Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.将 King's 简短间质性肺病问卷(K-BILD)翻译成法语、意大利语、瑞典语和荷兰语,并进行验证。
Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.
5
The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.《国王间质性肺病(KBILD)问卷》:更新的最小临床重要差异。
BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.
6
Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者中 King's 简短间质性肺病问卷的验证。
BMC Pulm Med. 2019 Dec 19;19(1):255. doi: 10.1186/s12890-019-1018-0.
7
Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.间质性肺疾病生活质量评估:疾病特异性 K-BILD 与通用 EQ-5D-5L 的比较。
Respir Res. 2018 May 25;19(1):101. doi: 10.1186/s12931-018-0808-x.
8
Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.SGRQ-I 和 K-BILD 在特发性肺纤维化中的反应性和最小临床重要差异。
Respir Res. 2020 Apr 21;21(1):91. doi: 10.1186/s12931-020-01359-3.
9
ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF.系统性硬化症相关间质性肺病与特发性肺纤维化患者的间质性肺病特异性健康相关生活质量比较。
BMJ Open Respir Res. 2020 Jun;7(1). doi: 10.1136/bmjresp-2020-000598.
10
Nutritional status and quality of life in interstitial lung disease: a prospective cohort study.间质性肺疾病患者的营养状况和生活质量:一项前瞻性队列研究。
BMC Pulm Med. 2021 Feb 5;21(1):51. doi: 10.1186/s12890-021-01418-5.

引用本文的文献

1
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.特发性肺纤维化和进行性肺纤维化的治疗:2023 年澳大利亚和新西兰胸科学会立场声明的修订版。
Respirology. 2024 Feb;29(2):105-135. doi: 10.1111/resp.14656. Epub 2024 Jan 11.
2
Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.肺功能测试在识别纤维化结节病中进行性肺部疾病的价值:一项前瞻性可行性研究的结果
Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(2):e2022011. doi: 10.36141/svdld.v39i2.12940. Epub 2022 Jun 29.
3
Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?
间质性肺疾病的健康相关生活质量:我们能在全球使用相同的概念吗?
Front Med (Lausanne). 2021 Oct 6;8:745908. doi: 10.3389/fmed.2021.745908. eCollection 2021.
4
Validation of a derived version of the IPF-specific Saint George's Respiratory Questionnaire.特发性肺纤维化特异性圣乔治呼吸问卷衍生版本的验证。
Respir Res. 2021 Oct 5;22(1):259. doi: 10.1186/s12931-021-01853-2.
5
Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.以患者为中心的间质性肺疾病结局研究:美国胸科学会官方研究声明。
Am J Respir Crit Care Med. 2021 Jul 15;204(2):e3-e23. doi: 10.1164/rccm.202105-1193ST.
6
Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis.成血管和成纤维血清标志物与结节病肺功能和生活质量的相关性。
PLoS One. 2021 Feb 22;16(2):e0247197. doi: 10.1371/journal.pone.0247197. eCollection 2021.
7
Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis.特发性肺纤维化患者的健康相关生活质量:系统评价和荟萃分析。
Eur Respir Rev. 2020 Nov 5;29(158). doi: 10.1183/16000617.0154-2020. Print 2020 Dec 31.
8
The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study.步行自行车对特发性肺纤维化患者生活质量和运动能力的影响:一项可行性研究。
Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):192-202. doi: 10.36141/svdld.v37i2.9433. Epub 2020 Jun 30.
9
Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review.利妥昔单抗治疗自身免疫性疾病相关间质性肺疾病:来自单一转诊中心的经验及文献综述
J Clin Med. 2020 Sep 23;9(10):3070. doi: 10.3390/jcm9103070.
10
Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis.SGRQ-I 和 K-BILD 在特发性肺纤维化中的反应性和最小临床重要差异。
Respir Res. 2020 Apr 21;21(1):91. doi: 10.1186/s12931-020-01359-3.